Pipeline AIM Biologicals AEZS-150 AEZS-130 (Macimorelin) Macimorelin Dx
About us
COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Our Mission
We are focused on leveraging our research and clinical development expertise to advance medicines that improve the quality of life of patients with significant unmet medical needs across a range of therapeutic areas.
Our Vision
Establish COSCIENS as a global leader in the development and commercialization of therapeutic and diagnostic assets that have the potential to enhance the lives of patients in need.
Our Values
We pledge to act with Integrity — comprising Fairness, Honesty and Perseverance especially when facing difficulties or challenges. In our everyday work, we focus on those values while upholding the highest ethical standards: Teamwork, Transparency, Innovation, and Integrity.